uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
16 Junio 2023 - 6:05AM
uniQure Announces Inducement Grants Under Nasdaq Listing Rule
5635(c)(4)
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced the grant of inducement equity awards to
Jeannette Potts, the Company’s newly hired Chief Legal and
Compliance Officer, and other newly hired employees.
The inducement awards to Ms. Potts consist of a
non-qualified option to purchase 81,300 ordinary shares of the
Company and 47,100 restricted share units. The option has an
exercise price of $20.18 per share, which is equal to the closing
price of the Company’s ordinary shares as reported by Nasdaq on
June 13, 2023 (the “Grant Date”). The option has a ten-year term
and will vest over four years, with 25% of the underlying shares
vesting on the first anniversary of the Grant Date and an
additional 6.25% of the shares vesting in approximately equal
quarterly installments over the twelve successive quarters
thereafter. The restricted share units vest in three approximately
equal annual installments beginning on June 13, 2024.
The Company also granted equity awards to 24
other employees as a material inducement to commencing their
employment. In the aggregate, those employees received 66,400
restricted share units and options to purchase 65,500 ordinary
shares of the Company. Each option has an exercise price of $20.18
per share, the closing price per ordinary share as reported by
Nasdaq on the Grand Date. Each option has a ten-year term and will
vest over four years, with 25% of the original number of shares
vesting on the first anniversary of the Grant Date and an
additional 6.25% of the shares vesting in approximately equal
quarterly installments over the twelve successive quarters
thereafter. The restricted share units vest in three approximately
equal annual installments beginning on June 13, 2024.
The aforementioned equity awards were approved
by the Company’s board of directors on June 13, 2023 and were
issued to newly hired employees as a material inducement to
commencing their employment with the Company in accordance with and
under Nasdaq Listing Rule 5635(c)(4).
About uniQure
uniQure is delivering on the promise of gene
therapy – single treatments with potentially curative results. The
recent approvals of our gene therapy for hemophilia B – an historic
achievement based on more than a decade of research and clinical
development – represents a major milestone in the field of genomic
medicine and ushers in a new treatment approach for patients living
with hemophilia. We are now leveraging our modular and validated
technology platform to advance a pipeline of proprietary gene
therapies for the treatment of patients with Huntington's disease,
refractory temporal lobe epilepsy, ALS, Fabry disease, and other
severe diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS:Chiara
RussoDirect: 617-306-9137Mobile:
617-306-9137c.russo@uniQure.com |
FOR MEDIA:Tom MaloneDirect:
339-970-7558Mobile:339-223-8541t.malone@uniQure.com |
Uniqure Nv (LSE:0EE0)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Uniqure Nv (LSE:0EE0)
Gráfica de Acción Histórica
De May 2023 a May 2024